Keyphrases
BRAF Inhibitor (BRAFi)
100%
BRAF V600E
56%
ERK Pathway
52%
Tumor
48%
MEK Inhibitor (MEKi)
38%
Melanoma
37%
Mitogen-activated Protein Kinase
28%
Langerhans Cell Histiocytosis
27%
Cyclin-dependent Kinase 4 (CDK4)
24%
Resistance Mechanisms
22%
In Cancer
20%
Phosphoinositide 3-kinase (PI3K)
20%
Mutant BRAF
18%
Targeted Therapy
16%
Cancer Cells
15%
AKT Pathway
15%
Extracellular Signal-regulated Kinase
14%
Therapeutic Strategies
14%
Anti-BCMA CAR-T
13%
BRAF-mutant Melanoma
13%
Mesothelioma Cells
13%
Meeting Report
13%
Subclonal mutations
13%
CAR T-cell Therapy
13%
Italy
13%
Inhibitor Activity
13%
Multiple Myeloma Patients
13%
MAPK Inhibitors
13%
Dopa Decarboxylase
13%
Cyclin-dependent Kinase 6 (CDK6)
13%
RAF Kinase
12%
Tumor Regression
12%
Phosphorylation
12%
BRAF mutant
12%
Kinase Inhibitor
11%
Degrader
11%
Tumor Cells
11%
RhoA
11%
Feedback Inhibition
11%
Kinase Inhibition
10%
Combination Therapy
10%
BRAF V600E mutation
10%
Acquired Resistance
9%
Human Cancer
9%
Therapy-resistant
9%
Kinase Cascade
9%
Dimerization
9%
Inhibitor Resistant
9%
Extracellular Signal-regulated Kinase Signaling
9%
Membrane-associated
9%
Medicine and Dentistry
Melanoma
40%
Mitogen-Activated Protein Kinase
40%
Neoplasm
34%
Langerhans Cell Histiocytosis
20%
MEK Inhibitor
20%
Programmed Cell Death
16%
Cancer Cell
15%
Combination Therapy
14%
Cancer
14%
CAR T-cell therapy
13%
Multiple Myeloma
13%
B Cell Maturation Antigen
13%
Malignant Neoplasm
13%
Tumor Regression
10%
Personalized Medicine
9%
Dendritic Cell
8%
Xenograft
8%
Immune Response
8%
Somatic Mutation
8%
Phosphotransferase
8%
Targeted Therapy
8%
Juvenile Xanthogranuloma
7%
Immune Checkpoint Inhibitor
7%
Growth Inhibition
6%
Oncology
6%
Breast Cancer
6%
Positive Feedback
6%
Fatty Acid Synthase
6%
MAPK1
6%
Cell Migration
6%
RNA Splicing
6%
Vemurafenib
6%
Selenoprotein
6%
Carcinoma Cell
6%
Mitogen Activated Protein Kinase 1
6%
Hematology
6%
Cancer Therapy
6%
Mesothelioma
6%
Non Small Cell Lung Cancer
6%
Krukenberg Tumor
6%
Protein Kinase B
6%
Melanoma Skin Cancer
6%
Therapy Resistance
6%
Biological Marker
6%
Immunotherapy
6%
In Vitro
6%
Disease
6%
Capmatinib
5%
Biochemistry, Genetics and Molecular Biology
Langerhans Cell
27%
Dimerization
27%
Kinase
20%
Phosphotransferase
20%
Product Inhibition
16%
MEK Inhibitor
15%
Aromatic L-Amino Acid Decarboxylase
13%
Extracellular Signal-Regulated Kinases
13%
MAP2K1
12%
Cancer Cell
12%
Vemurafenib
10%
Drive
10%
Rebound
10%
Oncogene
10%
Proteomics
10%
Cooperation
10%
Phosphoinositide 3-Kinase
9%
Mitogen-Activated Protein Kinase
9%
Drug Resistance
9%
Protomer
9%
KRAS
9%
Somatic Mutation
8%
Dendritic Cell
8%
Guanosine Triphosphate
8%
Tumor Suppressor Protein
8%
Signal Transduction
8%
Cell Migration
8%
Small Molecule
8%
Wild Type
7%
Cell Death
7%
CTLA-4
6%
Immune Checkpoints
6%
Autoinhibition
6%
Allosteric Site
6%
RNA Splicing
6%
Lymphocyte Activation
6%
Janus Kinase 1
6%
Mechanistic Target of Rapamycin
6%
Immunogenicity
6%
Sodium-Hydrogen Antiporter
6%
Gene Expression Profiling
6%
Protein Kinase C
6%
Cystic Fibrosis Transmembrane Conductance Regulator
6%
Positive Feedback
6%
Developmental Stage
6%
Tyrosine Kinase Inhibitor
6%
Mediterranean Fruit Fly
6%
ROCK1
6%
Dabrafenib
6%
Fibrinogen
6%
